IRAKLIA Study

Myeloma Paper of the Day, February 6th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Phase 3 CEPHEUS study of Dara+VRd vs. VRd finds MRD-negativity 60.9% for quad vs. 39.4% with VRd; ≥CR rates 81.2% vs. 61.6%; sustained MRD negativity (≥12 mos) 48.7% vs. 26.3%, giving 43% lower progression or death risk.”

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study

Authors: Saad Z. Usmani et al.

Myeloma Paper of the Day, February 6th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.

Bortezomib cancer CEPHEUS study Daratumumab Lenalidomide MD Anderson Cancer Center Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Saad Z. Usmani